Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population | Zendy

Arzu Okyar Baş | Zendy; Merve Hafızoğlu | Zendy; Filiz Akbıyık | Zendy; Merve Güner | Zendy; Z. Şahiner | Zendy; Serdar Ceylan | Zendy; Pelin Ünsal | Zendy; Burcu Balam Doğu | Zendy; Mustafa Cankurtaran | Zendy; B. Çakır | Zendy; Serhat Ünal | Zendy; Meltem Halil | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population

Author(s) -

Arzu Okyar Baş,

Merve Hafızoğlu,

Filiz Akbıyık,

Merve Güner,

Z. Şahiner,

Serdar Ceylan,

Pelin Ünsal,

Burcu Balam Doğu,

Mustafa Cankurtaran,

B. Çakır,

Serhat Ünal,

Meltem Halil

Publication year - 2022

Publication title -

age and ageing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.014

H-Index - 143

eISSN - 1468-2834

pISSN - 0002-0729

DOI - 10.1093/ageing/afac088

Subject(s) - medicine , vaccination , turkish population , population , antibody , antibody response , immunology , biochemistry , chemistry , environmental health , genotype , gene

Sars-CoV-2 infection influences older individuals at the forefront, and there is still limited data on the COVID-19 vaccine response in the geriatric population. This study aimed to assess antibody response after vaccination with SARS-CoV-2 inactivated vaccine and examine possible factors affecting this response in a geriatric population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research